Baxalta (Baxalta) Short-Term Debt & Capital Lease Obligation : $307 Mil (As of Mar. 2016)

View and export this data going back to 2015. Start your Free Trial

What is Baxalta Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Baxalta's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2016 was $307 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Baxalta's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2016 was $5,317 Mil.

Baxalta Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Baxalta's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxalta Short-Term Debt & Capital Lease Obligation Chart

Baxalta Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Short-Term Debt & Capital Lease Obligation

3.00

Baxalta Quarterly Data
	Dec12	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial						-	-	2.00	3.00	307.00

Baxalta Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Baxalta Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Baxalta's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Baxalta (Baxalta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baxalta Inc (NYSE:BXLT) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.baxalta.com

Baxalta Inc was incorporated on September 8, 2016. It is a biopharmaceutical company engaged in the field of unmet medical needs covering various diseases which includes haemophilia, immunology and oncology. The Company develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia. It also invests in emerging technology platforms, including gene therapy and biosimilars. Its competitors include Advate, Feiba, Gammagard. The Company is subject to rules and regulations put forth by the jurisdiction it operates in.

Executives

Gail D Fosler	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
John Glasspool	officer: See Remarks	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Dagmar Rosa-bjorkeson	officer: EVP and President, Biosimilars	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
David D. Meek	officer: EVP and President, Oncology	3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Karen Jean Ferrante	director	150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Peter G Edwards	officer: SVP and General Counsel	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Robert J. Hombach	officer: EVP. CFO and COO	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Blake E Devitt	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Wayne T Hockmeyer	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anne-marie Law	officer: EVP & Head of Human Resources	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Stroucken Albert P L	director	BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Gavin James R Iii	director	BAXTER INTERNATIONAL INC, ONE BAXTER PARKWAY, DEERFIELD IL 60015
John D Forsyth	director	C/O BAXTER INTERNATIONAL, ONE BAXTER PARKWAY, DEERFIELD IL 60015
Ludwig Hantson	director, officer: President and CEO	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921